NO20110582L - Mutasjon av parkingen, preparater, fremgangsmater og anvendelser - Google Patents

Mutasjon av parkingen, preparater, fremgangsmater og anvendelser

Info

Publication number
NO20110582L
NO20110582L NO20110582A NO20110582A NO20110582L NO 20110582 L NO20110582 L NO 20110582L NO 20110582 A NO20110582 A NO 20110582A NO 20110582 A NO20110582 A NO 20110582A NO 20110582 L NO20110582 L NO 20110582L
Authority
NO
Norway
Prior art keywords
gene
parkin
exons
deletion
amplifying
Prior art date
Application number
NO20110582A
Other languages
English (en)
Other versions
NO333907B1 (no
Inventor
Sylvain Ricard
Alexis Brice
Nacer Eddine Abbas
Patrice Denefle
Christophe Lucking
Sandrine Buoley
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9814524A external-priority patent/FR2786199B1/fr
Priority claimed from FR9910140A external-priority patent/FR2797272B1/fr
Publication of NO20110582L publication Critical patent/NO20110582L/no
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of NO333907B1 publication Critical patent/NO333907B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
    • C12Y603/02019—Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO20110582A 1998-11-19 2011-04-14 Nukleinsyre som koder for en deletert form av h-parkin, polypeptid, antistoff, sammensetning, probe, fremgangsmåter, vektor, celle, ikke-humant pattedyr samt anvendelse. NO333907B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9814524A FR2786199B1 (fr) 1998-11-19 1998-11-19 Mutations du gene de la parkine, compositions, methodes et utilisations
US12423999P 1999-03-12 1999-03-12
FR9910140A FR2797272B1 (fr) 1999-08-04 1999-08-04 Nouvelles mutations du gene de la parkine, compositions, methodes et utilisations
PCT/FR1999/002833 WO2000031253A2 (fr) 1998-11-19 1999-11-18 Mutations du gene de la parkine, compositions, methodes et utilisations

Publications (2)

Publication Number Publication Date
NO20110582L true NO20110582L (no) 2001-07-18
NO333907B1 NO333907B1 (no) 2013-10-14

Family

ID=27253486

Family Applications (5)

Application Number Title Priority Date Filing Date
NO20012342A NO330896B1 (no) 1998-11-19 2001-05-11 Nukleinsyre som koder for en mutert form av h-parkin, polypeptid, antistoff,sammensetning, probe, fremgangsmater, vektor, celle, ikke-humant pattedyr samt anvendelser.
NO20110582A NO333907B1 (no) 1998-11-19 2011-04-14 Nukleinsyre som koder for en deletert form av h-parkin, polypeptid, antistoff, sammensetning, probe, fremgangsmåter, vektor, celle, ikke-humant pattedyr samt anvendelse.
NO20110577A NO332174B1 (no) 1998-11-19 2011-04-14 Nukleinsyre som koder for humant parkin, polypeptid, antistoff, sammensetning, probe, fremgangsmate, vektor, celle, ikke-humant pattedyr samt anvendelse
NO20110580A NO333906B1 (no) 1998-11-19 2011-04-14 Nukleinsyre som koder for en deletert form av h-parkin, polypeptid, antistoff, sammensetning, probe, fremgangsmåter, vektor, celle, ikke-humant pattedyr samt anvendelse
NO20110578A NO332173B1 (no) 1998-11-19 2011-04-14 Nukleinsyre som koder for humant parkin, polypeptid, antistoff, sammensetning, probe, fremgangsmate, vektor, celle, ikke-humant pattedyr samt anvendelse.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20012342A NO330896B1 (no) 1998-11-19 2001-05-11 Nukleinsyre som koder for en mutert form av h-parkin, polypeptid, antistoff,sammensetning, probe, fremgangsmater, vektor, celle, ikke-humant pattedyr samt anvendelser.

Family Applications After (3)

Application Number Title Priority Date Filing Date
NO20110577A NO332174B1 (no) 1998-11-19 2011-04-14 Nukleinsyre som koder for humant parkin, polypeptid, antistoff, sammensetning, probe, fremgangsmate, vektor, celle, ikke-humant pattedyr samt anvendelse
NO20110580A NO333906B1 (no) 1998-11-19 2011-04-14 Nukleinsyre som koder for en deletert form av h-parkin, polypeptid, antistoff, sammensetning, probe, fremgangsmåter, vektor, celle, ikke-humant pattedyr samt anvendelse
NO20110578A NO332173B1 (no) 1998-11-19 2011-04-14 Nukleinsyre som koder for humant parkin, polypeptid, antistoff, sammensetning, probe, fremgangsmate, vektor, celle, ikke-humant pattedyr samt anvendelse.

Country Status (15)

Country Link
US (3) US8835618B2 (no)
EP (5) EP2128257A3 (no)
JP (1) JP5424519B2 (no)
AT (1) ATE440138T1 (no)
AU (1) AU778281B2 (no)
CA (1) CA2351567C (no)
CY (1) CY1110535T1 (no)
DE (1) DE69941300D1 (no)
DK (1) DK1131424T3 (no)
ES (1) ES2330281T3 (no)
IL (3) IL142755A0 (no)
NO (5) NO330896B1 (no)
NZ (1) NZ512313A (no)
PT (1) PT1131424E (no)
WO (1) WO2000031253A2 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1081225A1 (en) * 1999-08-30 2001-03-07 Biofrontera Pharmaceuticals GmbH Transgenic animal model for neurodegenerative diseases
US20040248092A1 (en) * 2000-05-26 2004-12-09 Vance Jeffrey M Methods of screening for parkinsons's disease
FR2845245A1 (fr) * 2002-10-07 2004-04-09 Aventis Pharma Sa Modele animal de la maladie de parkinson
US7790390B2 (en) 2004-10-27 2010-09-07 Duke University Methods for identifying an individual at increased risk of developing coronary artery disease
US7807465B2 (en) 2004-10-27 2010-10-05 Duke University Methods for identifying an individual at increased risk of developing coronary artery disease
CN110295147A (zh) * 2019-07-22 2019-10-01 新乡医学院 一种食管癌细胞系中功能基因敲除后增殖表型的快速鉴定方法及其应用
CA3179402A1 (en) * 2020-05-21 2021-11-25 Jennifer Johnston Gene therapy delivery of parkin mutants having increased activity to treat parkinson's disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817478A (en) * 1993-10-05 1998-10-06 Asahi Glass Company Ltd. Multicloning vector, expression vector and production of foreign proteins by using the expression vector
CN1151269C (zh) 1995-06-06 2004-05-26 扬·维吉 用于诊断性dna检测的方法
WO1999040191A1 (fr) * 1998-02-09 1999-08-12 Boehringer Ingelheim International Gmbh Adn ou genes contribuant au developpement de la maladie de parkinson
CA2996759A1 (fr) * 1998-11-19 2000-06-02 Aventis Pharma S.A. Mutations du gene de la parkine, compositions, methodes et utilisations

Also Published As

Publication number Publication date
US20150074836A1 (en) 2015-03-12
CY1110535T1 (el) 2015-04-29
WO2000031253A3 (fr) 2000-09-28
EP2345722A1 (fr) 2011-07-20
ES2330281T3 (es) 2009-12-07
IL142755A0 (en) 2002-03-10
EP2311954A1 (fr) 2011-04-20
AU778281B2 (en) 2004-11-25
NO333906B1 (no) 2013-10-14
IL142755A (en) 2009-08-03
CA2351567A1 (fr) 2000-06-02
EP2305816A1 (fr) 2011-04-06
NO20110577L (no) 2001-07-18
NO333907B1 (no) 2013-10-14
PT1131424E (pt) 2009-10-23
NO332174B1 (no) 2012-07-16
NO20110578L (no) 2001-07-18
US9540693B2 (en) 2017-01-10
DE69941300D1 (de) 2009-10-01
JP5424519B2 (ja) 2014-02-26
NO332173B1 (no) 2012-07-16
EP2128257A2 (fr) 2009-12-02
NO20110580L (no) 2001-07-18
US20170183736A1 (en) 2017-06-29
US8835618B2 (en) 2014-09-16
JP2002536961A (ja) 2002-11-05
EP2128257A3 (fr) 2010-03-03
NO20012342L (no) 2001-07-18
NO330896B1 (no) 2011-08-08
AU1276900A (en) 2000-06-13
NZ512313A (en) 2003-12-19
CA2351567C (fr) 2016-01-12
EP1131424A2 (fr) 2001-09-12
DK1131424T3 (da) 2009-11-23
ATE440138T1 (de) 2009-09-15
WO2000031253A2 (fr) 2000-06-02
EP1131424B1 (fr) 2009-08-19
NO20012342D0 (no) 2001-05-11
US20120064598A1 (en) 2012-03-15
IL187652A (en) 2010-02-17

Similar Documents

Publication Publication Date Title
NO20110577L (no) Mutasjon av parkingen, preparater, fremgangsmater og anvendelser
Kılınç et al. Human population dynamics and Yersinia pestis in ancient northeast Asia
ATE269416T1 (de) Verwendung von vereinigten sonden zur genetischen analyse
ATE310819T1 (de) Säugetieren apoptosis inhibitorprotein genfamilie,primers, probes und verfahren zur nachweis
Nakano et al. Variants in pancreatic carboxypeptidase genes CPA2 and CPB1 are not associated with chronic pancreatitis
JP2002521065A5 (no)
JP2003517830A5 (no)
AU614489B2 (en) Compositions and methods for clones containing dna sequences associated with multidrug resistance in human cells
Owerbach et al. Inheritance of a parotid secretory protein in mice and its use in determining salivary amylase quantitative variants
Broome et al. Non‐invasive transgenic mouse genotyping using stool analysis
Levenson Mechanisms of copper conservation in organs
Van Zutphen Serum esterase genetics in rabbits. II. Genetic analysis of the prealbumin esterase system, including atropinesterase and cocainesterase polymorphism
Karim et al. Molecular genetic study of a large inbred Pakistani family affected with autosomal recessive congenital ichthyosis through whole exome sequencing
ATE373095T1 (de) Mutierte muskelspezifische enhancer
ATE315104T1 (de) Glaukom diagnose und behandlung
WO2002086113A3 (en) Enzyme and snp marker for disease
CN101240325A (zh) 一种检测遗传基因修复能力的试剂盒
Silverton CRIME AND THE SCHIZOPHRENIA SPECTRUM: A STUDY OF TWO DANISH COHORTS.
Henry Differentiation of allozyme loci to distinguish between two species of Eisenia
EP1446485A4 (en) DIAGNOSIS PROCEDURE FOR CANCER MARKED BY IDENTIFICATION OF THE DELETION OF THE G-CSF EXONS 3
Friedberg et al. Calculation and verification of the ages of retroprocessed pseudogenes
Zeng et al. Screening and mutation analysis of phenylalanine hydroxylase deficiency in newborns from Jiangxi province
Harris Mutagenicity of chemicals and drugs
Basset et al. Identification of three Sorex species with microsatellite markers
CN117925850A (zh) 一种与泥蚶血红素浓度相关的snp位点及其在亲本选育中的应用

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees